24.74
0.28 (1.14%)
| 前收盘价格 | 24.46 |
| 收盘价格 | 24.27 |
| 成交量 | 1,743,224 |
| 平均成交量 (3个月) | 2,950,883 |
| 市值 | 3,935,134,976 |
| 价格/销量 (P/S) | 12.83 |
| 股市价格/股市净资产 (P/B) | 28.34 |
| 52周波幅 |
| 营业毛利率 | -74.84% |
| 营业利益率 (TTM) | -56.45% |
| 稀释每股收益 (EPS TTM) | -0.950 |
| 季度收入增长率 (YOY) | 25.20% |
| 总债务/股东权益 (D/E MRQ) | 115.90% |
| 流动比率 (MRQ) | 2.92 |
| 营业现金流 (OCF TTM) | -85.34 M |
| 杠杆自由现金流 (LFCF TTM) | -21.40 M |
| 资产报酬率 (ROA TTM) | -15.05% |
| 股东权益报酬率 (ROE TTM) | -61.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Adaptive Biotechnologies Corpor | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 2.35% |
| 机构持股比例 | 98.36% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BOBULSKY SUSAN | - | 25.45 | -3,000 | -76,350 |
| 累积净数量 | -3,000 | |||
| 累积净值 ($) | -76,350 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 25.45 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BOBULSKY SUSAN | 职员 | 10 Aug 2026 | 自动卖出 (-) | 3,000 | 25.45 | 76,350 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合